Colorado BioScience Association Announces Record-Breaking Attendance at Vail Investor Conference
By: Colorado BioScience Association Date: 09/06/2022
Rocky Mountain Life Sciences Investor & Partnering Conference to Welcome More than 200 Attendees
Denver – Colorado BioScience Association (CBSA) will highlight the future of health innovation at the Rocky Mountain Life Sciences Investor and Partnering Conference in Vail, Colo. on September 13 and 14. The conference connects the region’s most promising life sciences companies with investors and strategic partners from across the country.
Returning for the first time since 2019, the conference will welcome more than 200 attendees, including 60 life sciences presenting companies. Other attendees at the event, held at the Grand Hyatt Vail, include investors and strategic partners, service providers, and industry thought leaders. The agenda includes pitches from 30 life sciences companies, inspiration from a leading advocate for leading-edge cancer treatments, insights on the life sciences investment landscape, and dedicated time for partnering and networking.
“The caliber of life sciences innovations from the Rocky Mountain West is attracting top investors and strategic partners from across the U.S.,” said Elyse Blazevich, President and CEO of Colorado BioScience Association. “With the record-breaking registrations, it will be a dynamic and productive conference for our presenting companies, investors, and strategic partners.”
Presenting companies include 30 medtech, biotechnology, pharmaceutical, and digital health innovators, seeking between $1.5 million and $100 million in funding.
|Aesthetics Biomedical||Funding Sought: $15M||Imidex||Funding Sought: $1.5M|
|Arpeggio||Funding Sought:||Medecipher Solutions||Funding Sought: $2M – $2.5M|
|Aspero Medical||Funding Sought: $5M||nView medical||Funding Sought: $10M|
|Burst Diagnostics||Funding Sought: $2.5M||Reglagene||Funding Sought: $3.5M|
|CaliberMRI||Funding Sought: $2.5M||RheumaGen||Funding Sought: $20M – $30M|
|Ceria Therapeutics||Funding Sought: $5M||Securisyn Medical||Funding Sought: $20M|
|Certus Critical Care||Funding Sought: $10M||SinuTec, Inc.||Funding Sought: $1.25M|
|ClinOne||Funding Sought: $8 – $10M||STAQ Pharma||Funding Sought: $30M|
|CorNav||Funding Sought: $5M||Think Bioscience||Funding Sought: Recently completed Seed. Interested in meeting potential partners and investor for Series A round.|
|EnteroTrack||Funding Sought: $10M||Validus Cellular Therapeutics||Funding Sought: $10M|
|Flourish Medical||Funding Sought: $2M||Vesicle Therapeutics||Funding Sought: $25M|
|ForCast Orthopedics||Funding Sought: $5M – $6M||Vibliome Therapeutics||Funding Sought: $50M|
|Foresight Diagnostics||Funding Sought:||vitro3D||Funding Sought: $2M|
|GelSana Therapeutics||Funding Sought: $8M||Vona Oncology||Funding Sought: $5M – $10M|
|HepQuant||Funding Sought: $20M – $100M||ZelosDx||Funding Sought: $1.5M|
The Rocky Mountain Life Sciences Investor and Partnering Conference will also feature thought leaders who will highlight the importance and impact of health innovations.
Keynote Speaker: Tom Whitehead, President and Co-Founder, Emily Whitehead Foundation
Emily Whitehead, Tom’s daughter, is alive today because of cutting-edge cancer research. As the first pediatric patient in the world to receive CAR T-cell therapy after a terminal acute lymphoblastic leukemia (ALL) prognosis, Emily is more than 10 years cancer-free. Tom speaks internationally to share Emily’s story and to raise awareness for pediatric cancer immunotherapy research.
Panel Discussion: Emerging Investment Trends to Propel Life-Saving Innovations
- Vikram Chaudhery, Ph.D., Partner at Genoa Ventures and Co-Founder & President of General Inception
- David Uffer, VP of Commercial Development, General Inception
- Kwame Ulmer, Venture Partner, Wavemaker Three-Sixty Health
- Elizabeth Wu, Ph.D., Director, Early Innovation Partnering, Johnson & Johnson Innovation
- Eric Zimmerman, Principal Healthcare & Life Sciences BD, Venture Capital & Startups, Amazon Web Services (AWS)
- Moderator: Michael Weiner, Partner, Dorsey and Whitney
Limited registrations for investors, strategic partners, and life sciences companies are available. Currently, CBSA is maintaining a wait list for service providers.
About Colorado BioScience Association
Colorado BioScience Association (CBSA) creates co-opportunity for the Colorado life sciences community. CBSA champions a collaborative life sciences ecosystem and advocates for a supportive business climate. From concept to commercialization, member companies and organizations drive global health innovations, products and services that improve and save lives. The association leads Capital and Growth, Education and Networking, Policy and Advocacy, and Workforce Cultivation to make its members stronger, together. Learn more: cobioscience.com
# # #
Primavera Group for Colorado BioScience Association